natgillin/translations-raw huggingface dataset:
The use of claim 21, wherein the medicament is intended for administration together with another active component selected from the group consisting of glucocorticoids, vitamin D analogues, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergenic agents, methyl xanthines, B-adregenic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, peniciliamine, serum cholesterol reducing agents, retinoids, zinc salts and salicylazosulfapyridin. 
Primjena prema patentnom zahtjevu 21, naznačena time što je lijek namijenjen za primjenu zajedno sa drugom aktivnom komponentom koja je izabrana iz grupe koju čine glukokortikoidi, analozi vitamina D, antihistaminici, antagonisti faktora aktivacije trombocita (PAF), antiholinergička sredstva, metil ksantini, B-adrenergička sredstva, inhibitori COX-2, salicilati, indometacin, flufenamat, naproksen, timegadin, soli zlata, peniciliamin, sredstva za snižavanje kolesterola u serumu, retinoidi, soli cinka i salicilazosulfapiridin.
The (2S)-5-amino-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid p-toluenesulfonate anhydrate according to claim 58, which is in crystalline form exhibiting main peaks at interplanar spacings d of 23.9, 11.9, 4.5, 4.3, and 3.6 angstroms in powder X-ray diffraction obtained by copper Ka radiation. 
Anhidrat p-toluensulfonata (2S)-5-amino-2-{[1-(trans-4-metilcikloheksil)-1H-imidazol-4-il]metil} valerične kiseline prema patentnom zahtjevu 47, koji je u kristalnom obliku koji pokazuje glavne vrhove na interplanarnim rastojanjima d od 23.9, 11.9, 4.5, 4.3, i 3.6 angstroma pri difrakciji X-zraka u prahu dobivenoj Ka zračenjem bakra.
an annular heating element is positioned against the inside of the shell 14 and a strip of the polyethylene coating is heated to its melting temperature; a previously assembled cup body 12 is then drawn by suction into the shell 14 until the annular periphery of the shoulder 31 of the cup body 22 seats along a contact path 3 against the shell at the melted strip, see Figure 11; 
- - prstenasti element za zagrijavanje se postavi na unutarnju stranu ljuske 14 i obloga od polietilenske trake se zagrije do temperature svojeg taljenja; prethodno načinjena čaša 22 se tada uvuče usisavanjem u ljusku 14 sve dok prstenasti obod izbočenja 31 tijela čaše ne nasjedne na ljusku na mjestu gdje se nalazi rastopljena traka, vidi sliku
The pharmaceutical composition of claim 27, further comprising another therapeutic agent. 
Farmaceutski sastav prema zahtjevu 29 ili 30, koji dalje obuhvaća drugo terapeutsko sredstvo.
On the other hand, the rear straps 32, 34 for the sides can be equipped with strips of elastic material at the relevant anchoring points of the intermediate connecting slots 20, 22 . 
Prilagodivi ortopedski korzet (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da su omogućene stražnje vrpce (32, 34), u svojim odgovarajućim točkama učvršćivanja za srednje povezne utore (20, 22), s trakama načinjenim od elastičnog materijala.
Nifuratel according to claim 9, characterized in that said at least one pH modifier is selected from: ascorbic acid, acetic acid, lactic acid, and salts thereof. 
Nifuratel, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan modifikator pH bira između: askorbinske kiseline, octene kiseline, mliječne kiseline, te njihovih soli.
The compound of claim 11 wherein R1 is phenyl. 
Spoj prema patentnom zahtjevu 11 pri čemu je R1 fenil.
a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 29, 31, 33, or 35. 
molekula nukleinske kiseline koja kodira polipeptid koji sadrži aminokiselinski odsječak SEQ ID NO: 29, 31, 33 ili 35.
A method for treating HIV infection or disease-in a mammalian subject comprising administering an effective amount of a phorbol ester of Formula II, a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, or polymorph thereof to said mammalian subject 
HR P20160902 T1 PATENTNI ZAHTJEVI Forbolski ester Formule II: rormusa li ili njegova farmaceutski prikladna sol, izomer, enantiomer, solvat, hidrat ili polimorf za uporabu u prevenciji ili liječenju HIV infekcije u subjekta koji je sisavac.
The wet mass was passed through mesh #08 and the wet granules dried in a tray dryer at 70° C. till the loss on drying was 0.65%. 
Mokra masa je prosijana kroz sito # 08 te su mokre granule osušene u sušioniku s kadicom na 70 "C dok gubitak pri sušenju nije bio 0,65 %.
additionally contains a preservative in an amount that in absence of tapentadol would not sufficiently preserve the pharmaceutical composition according to the Ph. 
(ii) dodatno sadrži konzervans u količini koja u nedostatku tapentadola ne bi dovoljno sačuvala farmaceutski pripravak u skladu s Ph.
The antibody for use according to any one of claims 1-4, wherein there is a post-administration reduction in absolute basophil count of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at least 70 basophils/mm3. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-4, naznačeno time da postoji smanjenje apsolutnog broja bazofila nakon davanja od barem 5, barem 10, barem 15, barem 20, barem 25, pri barem 30, barem 35, barem 40, najmanje 45, barem 50, barem 55, barem 60, barem 65 ili barem 70 bazofila/mm".
According to a preferred embodiment of the present invention the peptide is coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole Limpet Hemocyanin). 
Peptid prema zahtjevu 11, naznačen time, da je peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
For example, the first colon cleansing solution is provided in a volume of 750 ml. 
Komplet u skladu s patentnim zahtjevom 17, naznačen time što prva otopina za čišćenje debelog crijeva sadrži:
A method for treating or delaying the progression or onset of Type 2 diabetes in humans comprising the step of administering to the human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2.
measuring the level of the SEPTIN9 gene expression and/or its promoter or regulatory elements or a fragment thereof, and optionally of the RASSF2A gene and/or its promoter or regulatory elements or a fragment thereof in blood obtained from the subject after the primary tumor has been removed by surgery and resection and prior to a treatment following the surgery or resection (post-treatment sample), whereby an increased or equivalent amount of the SEPTIN9 gene expression and/or its promoter or regulatory elements or a fragment thereof, and optionally of the RASSF2A gene and/or its promoter or regulatory elements or a fragment thereof in the post-treatment sample following surgery and resection compared to the pre-treatment sample indicates a bad prognosis, 
HR P20180001 T1 elemenata ili njegovog fragmenta u krvi koja je dobivena od subjekta prije uklanjanja primarnog tumora operacijom ili resekcijom (uzorak prije liječenja); mjerenje nivoa ekspresije SEPTINO gena i/ili njegovog promotora ili regulatornih elemenata ili njegovog fragmenta, i izborno RASSF2A gena i/ili njegovog promotora ili regulatornih elemenata ili njegovog fragmenta u krvi koja je dobivena od subjekta nakon što je primarni tumor bio uklonjen operacijom ili resekcijom i prije liječenja nakon operacije ili resekcije (uzorak prije liječenja), čime ekspresija povećane ili ekvivalentne količine SEPTINO gena i/ili njegovog promotora ili regulatornih elemenata ili njegovog fragmenta, i izborno RASSF2A gena iii njegovog promotora ili regulatornih elemenata ili njegovog fragmenta u uzorku nakon liječenja nakon operacije i resekcije uspoređena sa uzorkom prije liječenja ukazuje na
Method for treating water at low cost, according to claim 12, wherein if the method is used for treating water for desalinization purposes, the mobile suction means is activated by the coordination means to avoid the thickness of the settled material to exceed 10 mm. 
Metoda niskih troškova za tretiranje vode, u skladu s bilo kojim od patentnih zahtjeva 1 do 9, pri čemu ako se metoda koristi za tretiranje vode u svrhu desalinizacije, mobilno sredstvo za usisavanje (5) se aktivira sredstvom za upravljanje kako bi se izbjeglo stvaranje naslaga nataloženog materijala debljine veće od 10 mm.
the average diameter of the nanoparticle is from about 10 nm to about 300 nm, optionally wherein the average diameter of the nanoparticle is from about 50 nm to about 200 nm or from about 80 nm to about 140 nm; and/or 
€) = prosječni promjer nanočestice je od oko 10 nm do oko 300 nm, pri čemu je prosječni promjer nanočestice opcijski od oko 50 nm do oko 200 nm ili od oko 80 nm do oko 140 nm; i/ili
a closed coolant loop extending through the LNG/coolant heat exchanger (B) and including at least one first heat exchanger (G1, G2), a coolant from the respective heat exchanger being passed through the LNG/coolant heat exchanger as a gas and leaving in a condensed state as to produce NG by thermal exchange; and a heating medium being used within the at least one first heat exchanger (G1, G2) as to provide coolant in a gaseous state, 
zatvoreni krug za rashladno sredstvo koji se proteže kroz izmjenjivač topline ukapljeni prirodni plin/frashladno sredstvo (B) i sadrži najmanje jedan prvi izmjenjivač topline (G1, G2), rashladno sredstvo 1z odgovarajućeg izmjenjivača topline prolazi kroz izmjenjivač topline ukapljeni prirodni plin/rashladno sredstvo kao plin 1 odlazi u kondenziranom stanju kako bi se izmjenom topline dobio prirodni plin; i - < medij za zagrijavanje koji se koristi u najmanje jednom prvom izmjenjivaču topline (G1, G2) kako bi se dobilo rashladno sredstvo u plinovitom stanju, -
Compound 20 was obtained as a yellow solid from compound 2 and 4-iodo-aniline by method C. 
Spoj 20 se dobiva kao žuta krutina iz spoja 2 i 4-jod-anilina pomoću postupka C.
A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule of claim 5 . The host cell of claim 7, wherein said host cell is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
Prokariotska ili eukariotska domaćinska stanica koja sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 8, pri čemu je navedena domaćinska stanica opcionalno barem jedna izabrana od E. koli BL21Star (DE3), druga ćelija E. koli, kvasca, COS-1, COS- 7, HEK293, BHK21, CHO, BSC-I1, Hep G2, 653, SP2/0, 293, HeLa, mijeloma ili stanica limfoma, ili bilo koji njihovi derivati, besmrtne ili transformirane stanice.
The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein RZ is (5-6 membered heteroaryl)-C1-4 alkyl substituted by methoxy or F. 
RZ je (5-10-člani heteroaril)-C1-4 alkil-supstituiran s metoksi ili F; ili RZ je cijanometil; ili RZ je metoksimetil.
A method according to the invention, wherein the target epitope recognized by the variable regions of the 3rd and 4th CH3 domain comprising polypeptide chain is the same as the target epitope recognized by the variable region of the 1st or the 2nd CH3-domain comprising polypeptide chain is therefore also herewith provided. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je ciljni epitop kojeg prepoznaju varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrži CH3 domenu različitu od ciljnog epitopa kojeg prepoznaje varijabilnu regiju prvog ili drugog polipeptidnog lanca koji sadrži CH3 domenu.
Then the container is pushed down spreading the segments of the rosette and falling to the bottom of the housing. 
Zatim se spremnik gurne dolje, pri čemu se segmenti rozete rašire i on padne na dno kućišta.
Those batches which prove suitable are used, whereas those batches presenting traces of crosslinked PMMA are discarded. 
One hrpa koja se pokažu da su prikladne, koriste se, dok se one hrpe koje pokazuju tragove umreženog PMMA odlažu.
The chimeric polypeptide for use according to any one of claims 1 to 6, wherein the chimeric polypeptide is a FVIIIFc monomer dimer hybrid. 
Kimerni polipeptid, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je kimerni polipeptid dimerni hibrid monomera FVIIIFc.
Fatigue and/or sleep impairment may be caused by or associated with various sources, such as, for example, sleep apnea, perimenopausal hormonal shifts, Parkinson's disease, multiple sclerosis (MS), depression, chemotherapy, or shift work schedules. 
Spoj u skladu sa zahtjevom 23, naznačen time, da je bolest izabrana iz skupine koju čine: apneja u snu, perimenopauzalni hormonalni pomaci, Parkinsonova bolest, multipla skleroza, depresija, kemoterapija te poremećaj zbog rada u smjenama.
Figure 2 shows a sectional illustration of the first exemplary embodiment. 
(32) Datum podnošenja prve prijave: 19.06.2007.
The antibody-like binding protein of claim 9 or 10, wherein: is 1 amino acid residue in length; 
Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 5 ili 6, naznačen time da: L, je duljine 1 ostatak amino kiseline;
The computer implemented method of claim 1, wherein repairing the invalid field includes disabling, by the computing device, the invalid field. 
Računalno implementirana metoda prema zahtjevu 1, naznačeno time da popravak (106) nevažećeg polja uključuje onemogućivanje (128), putem računala (16), nevažećeg polja.
The composition of claim 1, which provides a Caves of 15 ng/ml to 35 ng/ml. 
Sastav prema bilo kojem od zahtjeva 1 do 3, koji osigurava C,,gg Od 15 ng/ml do 35 ng/ml.
and R2, equal or different from each other, are selected from the group comprising -H or a linear or branched alkyl group having 1 to 6 carbons, 
R; i R,, jednaki ili međusobno različiti, izabiru se iz grupe koja obuhvaća -H ili linearnu ili razgranatu alkilnu skupinu s 1 do 6 ugljika, 10
EPMATHMARKEREP where S is the concentration of radioligand and Kd is the dissociation constant. 
Ki = ICgy/1 + [SVKd gdje S predstavlja koncentraciju radioaktivnog liganda i Kd je konstanta disocijacije.
The method as described in claim 1 wherein the pellets (66) are hydrophobic at temperatures below approximately 60 °C (140 °F). 
Postupak kako je opisano u zahtjevu 1 naznačen time da su peleti (66) hidrofobni na temperaturama ispod približno 60C (140"F).
A method of any of claims 1 to 8, wherein the juice is contacted with the cation exchange resin and/or the anion exchange resin at an average flow rate of about 2 bv/hr to about 30 bv/hr. 
svježi sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu otprilike 1 prema 1; ili razrijeđeni sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu oko 1.4-2 prema 1.
The composition of claim 23, wherein the isolated keratin proteins are water insoluble B-keratin proteins. 
Sastav u skladu sa zahtjevom 23, naznačen time, što su izolirani keratin proteini vodno netopljivi f-keratin proteini.
a hollow tube bundle, including several hollow tubes, where an upper part of the hollow tube bundle is entirely inserted into the tube insertion cavity; a container, mounted at a lower end portion of a hollow tube by using an elastic fastener, where an inner cavity of the container is in communication with an inner passage of the hollow tube; and a holding mechanism, mounted on the joint at the tube insertion cavity, where the holding mechanism enables the tube insertion cavity to contract and hold the hollow tube bundle. 
snop šupljih cijevi (4), koji sadrži više šupljih cijevi, gdje gornji dio snopa se umetne u navedenu šupljinu za cijevi, i - spremnike, ugrađene na donjem dijelu šupljih cijevi uz pomoć elastičnog elementa za pričvršćivanje, gdje je unutarnja šupljina svakog spremnika spojena s unutarnjim kanalima šupljih cijevi; naznačen time što dodatno ima ograničavajući element, ugrađen na konektoru blizu šupljine za cijevi, gdje ograničavajući element smanjuje šupljinu za cijevi i imobilizira snop šupljih cijevi.
feeding the process gas to said saturator obtaining a gaseous stream (iv) leaving the head of the saturator; 
- puštanju procesnog plina u navedeni saturator, iz kojeg izlazi struja plina (iv) koja izlazi iz vrha saturatora;
EP 14154136.7 filed Feb. 6, 2014 and Swiss Patent Application No. 
EP 14154136.7 Datum podnošenja europske prijave patenta: 06.02.2014.
The T cell according to any one of claims 1-5, wherein the T cell further comprises an exogenous co-stimulatory ligand selected from the group consisting of OX40L, CD70, LIGHT, CD30L and CD86. 
T-stanica prema zahtjevu 16, naznačena time da je navedeni drugi rekombinantni ko-stimulacijski ligand odabran iz skupine koju čine OX40L, CD70, LIGHT, CD30L i CD86.
GRN163L for use in the treatment of cancer, wherein said treatment consists of administration of at least about 1.6 mg/kg to about 20 mg/kg of GRN163L on day 1 and on approximately day 8 of a 21 day cycle. 
GRN163L za uporabu u liječenju raka, gdje se to liječenje sastoji od primjene najmanje oko 1.6 mg/kg do oko 20 mg/kg GRN163L na dan 1 i otprilike na dan 8 u ciklusu od 21 dana.
Fuel supply arrangement according to claim 8, characterized in that said second volumetric flow rate is the maximum volumetric flow rate to be supplied to said engine (2) during normal operation of said engine. 
Uređaj za snabdijevanje gorivom u skladu s patentnim zahtjevom 6, naznačen time što je navedeni drugi volumni protok maksimalni volumni protok s kojim se snabdijeva navedeni motor (2) za vrijeme normalnog pogona navedenog motora.
The use of any one of the preceding items, wherein the gene encodes a therapeutic RNA, or a therapeutic protein selected from growth factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, any protein known to be mutated in pathological disorders such as the "survival of motor neuron" protein (SMN). 
AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova. AAV vektor 1z bilo kojeg od prethodnih patentnih zahtjeva, pri čemu gen kodira terapijsku RNA, ili terapijski protein odabran između čimbenika rasta, citokina, hormona, neurotransmitera, enzima, antiapoptotičkih čimbenika, angiogenih čimbenika 1 proteina, preživljavanja motoričkih neurona" (SMN).
converting the compound of formula (II) in the corresponding acid dichloride and using it as an intermediate compound for the preparation of the desired compounds of formula (III). 
pretvorbu tvari formule (II) u diklorid odgovarajuće kiseline, u prisustvu tionil klorida, kondenziranje dobivenog diklorida s kloridom 2-[(acetiloksi)]propionske kiseline zbog dobivanja odgovarajućeg 5-karboksamido derivata, i
The process of para 1 wherein the silyl chloride is tert -butyldimethylsilyl chloride, the sulfonyl chloride is methanesulfonyl chloride, the bases in step (d) are DMAP and TEA and the non-polar aprotic solvent is DCM and in step (e) the organic solvent is dioxane. 
Postupak prema zahtjevu 1, naznačen time, da sililklorid je fert-butildimetilsililklorid, sulfonilklorid je metansulfonilklorid, baze u koraku (d) su DMAP i TEA te nepolarno aprotičko otapalo je DCM, a u koraku (e) organsko otapalo je dioksan.
wherein: is selected from the group consisting of 
G' je odabran iz skupine koju čine i R';
The vaccine of claim 1, wherein the recombinant Mycobacterium bovis cell carries an antibiotic resistance gene, e.g. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1, naznačena time što rekombinantna Mycobacterium bovis stanica nosi gen za rezistenciju na antibiotike, npr.
The compound or salt of claim 69 wherein said myeloproliferative disorder (MPD) is essential thrombocythemia (ET). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
The cement admixture as recited in claim 3, wherein the calcium ferroaluminate has a fineness of 2,000 to 7,000 cm2/g in terms of a Blaine's specific surface area value. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što kalcijev feroaluminat ima finoću od 2000 do 7000 cm"/g u terminima vrijednosti Blaineove specifične površine.
The cell-binding agent maytansinoid conjugate of claim 1, for use in treating a cancer that expresses the Her2 antigen. 
Sredstvo za vezanje stanice konjugata majtanzinoida prema zahtjevu 1, naznačeno time, da se upotrebljava za liječenje raka koji izražava antigen Her2.
in part (c), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:117 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:116; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 117 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 116;
A compound of any one of claims 1-12 for use in the prevention, treatment or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. The compound for use according to claim 14, wherein said disease or condition is cancer, polycythemia vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukemia (CML), rheumatoid arthritis, inflammatory bowel syndrome, Chron's disease, psoriasis, contact dermatitis or delayed hypersensitivity reactions. 
Spoj za uporabu prema zahtjevu 3, naznačen time, da se upotrebljava u prevenciji, liječenju ili smanjivanju težine bolesti ili stanja koja/koje je odabrana/odabrano od sljedećih: rak, policitemija vera, esencijalna trombocitoza, mijelofibroza, kronična mijelogena leukemija (CML), reumatoidni artritis, kronična upalna crijevna bolest, Crohnova bolest, psorijaza, kontaktni dermatitis ili odgođene hipersenzitivne reakcije.
Composition according to any one of claims 1 to 4, wherein the bioadhesive material is selected from the group consisting of copolymers of acrylic acid or methacrylic acid with a (C10-C30)alkyl acrylate optionally crosslinked with allyl sucrose, allyl pentaerythritol or divinyl glycol. Composition according to any one of claims 1 to 5, wherein the average particle size of the particles of the complex of the active agent with the ion-exchange resin is preferably about 10 to about 3000 µm, particularly about 30 to about 2000 µm, and most preferably about 50 to about 1000 µm and/or the average particle size of the coated particles is preferably about 20 to about 5000 µm, particularly about 50 to about 4000 µm, and most preferably about 70 to about 3000 µm. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time,da prosječna veličina čestice od čestica u kompleksu djelatne tvari sa smolom ionske izmjene, iznosi 10 do 3000 um, posebno 30 do 2000 um i najpoželjnije 50 do 1000 um, i/ili prosječna veličina čestice od obloženih čestica iznosi 20 do 5000 um, posebno 50 do 4000 um i najpoželjnije 70 do 3000 um, i/ili obložene čestice imaju specifičnu težinu u rasponu od 1,1 do 2,0 i poželjno od 1,2 do 1,8, i/ili obložene čestice posjeduju specifično površinsko područje u rasponu od 1 do 200 m"/g.
As previously stated, harvesting equipment exist that are self-propelled and direct harvested crop into an on-board bin, a wagon pulled by the harvester, or a wagon pulled along-side the harvester by separate tractor. 
Kao što je ranije rečeno, postoji žetelačka oprema koja ima vlastiti pogon i usmjerava požnjeven usjev u bunker na vozilu, u prikolicu koju vuče žetelica, ili u prikolicu koju vuče posebni traktor uz žetelicu.
FIG. 6 shows a cross sectional view of a extraction module in the open state comparable to FIG. 
Slika 6 - prikazuje pogled na poprečni presjek modula za ekstrakciju u otvorenom položaju koji se može usporediti sa slikom 3,